Product Reports Resources Pricing Login Book a demo

AES

Biotech & Life Sciences · Horsham Township, United States · Founded 1998

Operated by Acurian, AES specializes in patient recruitment and site solutions for clinical trials MoreLess

Accelerated Enrollment Solutions (AES) operates as a business unit of the global contract research organization (CRO) PPD, which is now a part of Thermo Fisher Scientific. Established in 2018, AES was formed to provide pharmaceutical and biotechnology companies with specialized site and patient enrollment solutions for clinical trials. The company's creation integrated the capabilities of several industry leaders, including Synexus, a global network of research sites; Acurian, a patient enrollment and retention specialist; and Optimal Research, which focuses on vaccines and oncology trials.

The core business of AES is to accelerate clinical trial timelines and provide budget certainty by optimizing patient recruitment and site management. The company serves sponsors and CROs by offering a model that can deliver a significant portion, or even all, of the required patient enrollment for a study from a unified network. This is achieved by identifying qualified patient populations first, using predictive enrollment models, and then activating sites accordingly, which reduces the number of underperforming or non-enrolling sites. This approach addresses major industry challenges, such as slow patient recruitment and investigator site capacity limitations.

AES's service portfolio is comprehensive, combining a vast network of over 180 dedicated research sites across five continents with advanced patient identification and engagement capabilities. Through strategic acquisitions, such as the global site business from Bioclinica in 2019, AES expanded its geographic footprint into key markets including China, Latin America, and Western Europe, complementing its existing presence in North America, Europe, and South Africa. The company offers differentiated services for a variety of indications and has developed specific solutions like the PatientAdvantage program, which integrates multiple services for a patient-centric approach, and a just-in-time model for oncology trials.

Keywords: clinical trial enrollment, patient recruitment, research site network, contract research organization, biopharmaceutical services, site and patient solutions, clinical research support, drug development, Synexus, Acurian, Optimal Research, PPD, trial acceleration, site conduct, patient access, global clinical trials, vaccine trials, oncology research, patient retention, clinical study support

Team profiled 34 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

3 investors on AES's cap table

Sourced from Dealroom's funding and investor records.

Series A 3 investors entered at this stage
Flatiron Partners
ProQuest Investments
EuclidSR Partners

Global footprint

Where AES has talent and traffic

Workforce by country
18 countries with
team presence
🇺🇸 United States55.8%
🇵🇱 Poland13.7%
🇬🇧 United Kingdom12.3%
🇿🇦 South Africa5.5%
🇭🇺 Hungary3.4%
Top 5 of 18 shown

Market sentiment

What the market is saying about AES

An AI-synthesized read of the highest-engagement posts about AES on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See AES on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.